Episode

Getting To A First Product Approval With Celcuity's Brian Sullivan

Podcast
Business Of Biotech
Published
Aug 17, 2026
Duration seconds
3016
Processing state
not_requested
Canonical source
https://www.buzzsprout.com/1011661/episodes/19636491-getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan.mp3
Audio
https://www.buzzsprout.com/1011661/episodes/19636491-getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan.mp3
JSON
/v1/public/podcasts/business-of-biotech-123501/episodes/getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan
Markdown
/podcast/business-of-biotech-123501/getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/business-of-biotech-123501/getting-to-a-first-product-approval-with-celcuity-s-brian-sullivan.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of...